Single Center, Open-label, Accelerated Titration, Multiple Dosing Study to Evaluate the Safety, Tolerability, Immune Response and Pre-efficacy of BVAC-B in Patients With Progressive or Recurrent HER2/Neu Positive Gastric Cancer After Failure to Standard Care

Trial Profile

Single Center, Open-label, Accelerated Titration, Multiple Dosing Study to Evaluate the Safety, Tolerability, Immune Response and Pre-efficacy of BVAC-B in Patients With Progressive or Recurrent HER2/Neu Positive Gastric Cancer After Failure to Standard Care

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Feb 2018

At a glance

  • Drugs BVAC-B (Primary)
  • Indications Gastric cancer
  • Focus Adverse reactions
  • Sponsors Cellid Company
  • Most Recent Events

    • 13 Feb 2018 New trial record
    • 24 Jan 2018 According to the Korea Food and Drug Administration (KFDA), Selid received approval for Phase 1 clinical trial of the new concept of the anti-cancer vaccine BVAC-B.
    • 24 Jan 2018 According to a Cellid Company media release, the trial will be performed in a single institution of the Severance Hospital of Yonsei University College of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top